Imunon, INC. (IMNN) — 8-K Filings

All 8-K filings from Imunon, INC.. Browse 30 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (30)

Imunon, Inc. Files 8-K for Financial Results — Mar 31, 2026 Risk: low
Imunon, Inc. filed an 8-K on March 31, 2026, reporting on its Results of Operations and Financial Condition. The filing includes financial statements and exhibi
8-K Filing — Dec 31, 2025
Imunon, Inc. Faces Delisting Concerns — Aug 28, 2025 Risk: high
Imunon, Inc. filed an 8-K on August 27, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, formerly known as Cel
Imunon, Inc. Files 8-K: Other Events & Financials — Jul 28, 2025 Risk: low
Imunon, Inc. filed an 8-K on July 28, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific details about
Imunon, Inc. Files 8-K with Key Corporate Updates — Jul 23, 2025 Risk: medium
Imunon, Inc. filed an 8-K on July 23, 2025, reporting events as of July 21, 2025. The filing indicates material modifications to the rights of security holders,
Imunon, Inc. Files 8-K: Other Events & Financials — Jul 22, 2025 Risk: low
Imunon, Inc. filed an 8-K on July 22, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific details about
Imunon, Inc. Faces Delisting Concerns, Director Changes — Jul 14, 2025 Risk: high
Imunon, Inc. filed an 8-K on July 14, 2025, reporting a notice of delisting or failure to satisfy continued listing rules, as well as changes in directors and o
Imunon, Inc. Files 8-K on Security Holder Rights and Bylaws — Jul 11, 2025 Risk: medium
Imunon, Inc. filed an 8-K on July 11, 2025, reporting material modifications to the rights of security holders, amendments to its articles of incorporation or b
Imunon, Inc. Files 8-K: Board and Compensation Updates — Jun 13, 2025 Risk: low
On June 13, 2025, Imunon, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing also includes
Imunon, Inc. Files 8-K for Other Events — Jun 9, 2025 Risk: medium
Imunon, Inc. (formerly Celsion Corp) filed an 8-K on June 9, 2025, reporting "Other Events." The filing does not contain specific details about the nature of th
Imunon, Inc. Faces Delisting Notice — May 30, 2025 Risk: high
Imunon, Inc. filed an 8-K on May 30, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company, formerly known as Celsio
Imunon, Inc. Files 8-K: Material Agreement, Equity Sales — May 27, 2025 Risk: medium
On May 23, 2025, Imunon, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other event
Imunon, Inc. Relocates Principal Executive Offices — May 22, 2025 Risk: low
On May 22, 2025, Imunon, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 997 Lenox Drive, Suite 100, Law
Imunon, Inc. Faces Delisting Concerns — May 20, 2025 Risk: high
Imunon, Inc. filed an 8-K on May 20, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company's principal executive off
Imunon, Inc. Files 8-K: Material Agreement & Equity Sales — May 13, 2025 Risk: medium
On May 12, 2025, Imunon, Inc. filed an 8-K report detailing a material definitive agreement and unregistered sales of equity securities. The filing also include
Imunon, Inc. Files 8-K — Mar 24, 2025 Risk: low
Imunon, Inc. filed an 8-K on March 24, 2025, reporting other events and financial statements. The company, formerly known as Celsion Corp and Cheung Laboratorie
Imunon, Inc. Files 8-K on Executive Changes and Financials — Feb 10, 2025 Risk: medium
Imunon, Inc. filed an 8-K on February 10, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain offic
Imunon, Inc. Faces Delisting Concerns — Nov 27, 2024 Risk: high
Imunon, Inc. filed an 8-K on November 27, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company, formerl
Imunon, Inc. Files 8-K: Officer/Director Changes & Compensation — Oct 7, 2024 Risk: medium
Imunon, Inc. filed an 8-K on October 7, 2024, reporting events as of October 2, 2024. The filing covers the departure of directors or certain officers, the elec
Imunon, Inc. Files 8-K Report — Sep 3, 2024 Risk: low
On September 3, 2024, Imunon, Inc. filed an 8-K report detailing "Other Events" and "Financial Statements and Exhibits." The filing does not disclose specific n
Imunon, Inc. Files 8-K: Procedural Update — Aug 1, 2024 Risk: low
Imunon, Inc. filed an 8-K on August 1, 2024, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific details abou
Imunon Secures $1.5M in Preferred Stock Financing — Jul 31, 2024 Risk: medium
On July 30, 2024, Imunon, Inc. entered into a Material Definitive Agreement, specifically a Securities Purchase Agreement, with an accredited investor. The agre
Imunon, Inc. Files 8-K with Regulatory Updates — Jul 30, 2024 Risk: low
Imunon, Inc. filed an 8-K on July 30, 2024, reporting on various events. The filing includes information related to Regulation FD disclosures, other events, and
Imunon, Inc. Announces Special Stockholder Meeting for Reverse Stock Split — Jun 13, 2024 Risk: medium
On June 13, 2024, Imunon, Inc. filed an 8-K report detailing a special meeting of stockholders scheduled for July 15, 2024. The primary purpose of this meeting
Imunon, Inc. Announces Director Departure and Election — May 20, 2024 Risk: medium
On May 15, 2024, Imunon, Inc. filed an 8-K report detailing the departure of Director Dr. Nicholas B. Costales and the election of Dr. Jonathan S. Roth as a new
Imunon, Inc. Files 8-K for Operations and Financials — May 13, 2024 Risk: low
Imunon, Inc. filed an 8-K on May 13, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits.
Imunon, Inc. Reports Director/Officer Changes & Compensatory Arrangements — May 8, 2024 Risk: medium
Imunon, Inc. filed an 8-K on May 8, 2024, reporting changes effective May 3, 2024. The filing covers the departure of directors or certain officers, the electio
Imunon, Inc. Terminates Merger with Eterna Therapeutics — Apr 11, 2024 Risk: medium
On April 10, 2024, Imunon, Inc. announced the termination of its previously announced merger agreement with Eterna Therapeutics, Inc. The termination was effect
Imunon, Inc. Files 8-K for Amendments and Financials — Mar 18, 2024 Risk: low
On March 15, 2024, Imunon, Inc. filed an 8-K report detailing amendments to its Articles of Incorporation and financial statements. The company, formerly known
Imunon, Inc. Reports Board and Executive Changes — Mar 12, 2024 Risk: medium
Imunon, Inc. announced on March 6, 2024, a change in its board of directors and executive compensation arrangements. The filing details the departure of certain

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX